Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.
Authors: Eramo A; LB Pharmaceuticals Inc, New York, New York., Correll CU; Department of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine, Hempstead, New York.; Northwell, New Hyde Park, New York.; Department of Child and Adolescent Psychiatry, Universitätsmedizin Charité Berlin, Berlin, Germany.; German Center for Mental Health, partner site Berlin, Berlin, Germany., Walling DP; CenExel Collaborative Neuroscience Research, Garden Grove, California., Kakar R; Segal Trials, Lauderhill, Florida., Bassani N; Worldwide Clinical Trials, Nottingham, United Kingdom., Callahan L; LB Pharmaceuticals Inc, New York, New York., Lee BP; LB Pharmaceuticals Inc, New York, New York., Prensky Z; LB Pharmaceuticals Inc, New York, New York., Vaino AR; LB Pharmaceuticals Inc, New York, New York., Kane JM; Department of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine, Hempstead, New York.; Northwell, New Hyde Park, New York.
Source: JAMA psychiatry [JAMA Psychiatry] 2026 Jul 01; Vol. 83 (7), pp. 682-693.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589550 Publication Model: Print Cited Medium: Internet ISSN: 2168-6238 (Electronic) Linking ISSN: 2168622X NLM ISO Abbreviation: JAMA Psychiatry Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2168-6238
DOI:10.1001/jamapsychiatry.2026.0428